Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2418361 | 0.98 | FDPS (0.40) | FDPSSMPD1MEN1MAPTKMT2A | |
| SCHEMBL10706328 | 0.98 | SMPD1 (0.43) | FDPSSMPD1MEN1MAPTKMT2A | |
| SCHEMBL29087510 | 0.98 | SMPD1 (0.43) | FDPSSMPD1MEN1MAPTKMT2A | |
| SCHEMBL3996360 | 0.94 | FDPS (0.39) | FDPSSMPD1MEN1MAPTKMT2A | |
| SCHEMBL3127114 | 0.86 | DGAT1 (0.40) | FDPSDGAT1 | |
| SCHEMBL15415012 | 0.85 | DGAT1 (0.36) | FDPSMEN1MAPTKMT2ADGAT1 | |
| SCHEMBL2239348 | 0.83 | FDPS (0.40) | FDPSSMPD1GGPS1 | |
| SCHEMBL28032435 | 0.81 | FDPS (0.39) | FDPSSMPD1MEN1MAPTKMT2A | |
| SCHEMBL27712614 | 0.80 | FDPS (0.44) | FDPSSMPD1MEN1MAPTKMT2A | |
| SCHEMBL17756699 | 0.80 | CYP4F2 (0.47) | FDPSSMPD1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 900 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024221952-A1 | NANO-DELIVERY SYSTEM OF NUCLEOTIDE DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-10-31 | — | — | WO | claimed |
| CN-109336815-B | Two-photon fluorescent probe for detecting hypochlorous acid in intracellular endoplasmic reticulum | 济南大学 | 2020-07-07 | — | — | CN | claimed |
| US-12630632-B2 | Bispecific HER2 and CD3 binding molecules | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4423126-B1 | METHODS OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | JANSSEN BIOTECH INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4733320-A2 | METHODS OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260103510-A1 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | JANSSEN BIOTECH INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260083860-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | POSEIDA THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4714504-A2 | SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260071005-A1 | BISPECIFIC HER2 AND CD3 BINDING MOLECULES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062501-A1 | BISPECIFIC HER2 AND CD3 BINDING MOLECULES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260042732-A1 | Sulfur-containing Compounds and Compositions Thereof for Delivery of Nucleic Acids | POSEIDA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20030049725-A1 | Anti-TNF antibodies, compositions, methods and uses | CENTOCOR ORTHO BIOTECH INC. | 2003-03-13 | — | — | US | disclosed |
| US-20030040044-A1 | Anti-dual integrin antibodies, compositions, methods and uses | CENTOCOR ORTHO BIOTECH INC. | 2003-02-27 | — | — | US | disclosed |
| US-20030017150-A1 | Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses | CENTOCOR, INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002097048-A2 | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002074916-A2 | REG-LIKE PROTEIN IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002072788-A2 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE-RELATED IMMUNGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002012502-A2 | ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012500-A2 | ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012501-A2 | ANTI-DUAL INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062501-A1 | BISPECIFIC HER2 AND CD3 BINDING MOLECULES | ERBB2, CD2, TNFRSF9 | FDPS 4768/4885SMPD1 3511/4885MEN1 4343/4885 |
| US-20260042732-A1 | Sulfur-containing Compounds and Compositions Thereof for Delivery of Nucleic Acids | ELAVL1, NSUN3, SLC10A1 | FDPS 2363/4885SMPD1 742/4885MEN1 2975/4885 |
| US-20260071005-A1 | BISPECIFIC HER2 AND CD3 BINDING MOLECULES | CD2, ERBB2, CD4 | FDPS 4788/4885SMPD1 3229/4885MEN1 4126/4885 |
| US-12630632-B2 | Bispecific HER2 and CD3 binding molecules | CD274, PDCD1LG2, CD2 | FDPS 4885/4885SMPD1 2101/4885MEN1 1514/4885 |
| US-20260103510-A1 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | IL23R, IL17A, IL15 | FDPS 4042/4885SMPD1 2717/4885MEN1 3698/4885 |
| US-20260083860-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | TRMT1L, SPPL2B, DNMT3A | FDPS 2277/4885SMPD1 1585/4885MEN1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.